B. Metzler seel. Sohn & Co’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-23,096
Closed -$1.47M 735
2025
Q1
$1.47M Hold
23,096
0.02% 419
2024
Q4
$1.1M Sell
23,096
-10,087
-30% -$517K 0.01% 512
2024
Q3
$1.9M Sell
33,183
-9,252
-22% -$530K 0.02% 402
2024
Q2
$2.22M Hold
42,435
0.02% 357
2024
Q1
$1.73M Hold
42,435
0.02% 405
2023
Q4
$1.57M Buy
42,435
+4,808
+13% +$181K 0.02% 411
2023
Q3
$1.44M Sell
37,627
-32,881
-47% -$1.35M 0.02% 389
2023
Q2
$2.54M Buy
70,508
+37,725
+115% +$1.29M 0.03% 320
2023
Q1
$1.25M Buy
+32,783
New +$1.54M 0.02% 398

Other funds holding HALO

B. Metzler seel. Sohn & Co's HALO Position: Q2 2025 in Review

B. Metzler seel. Sohn & Co sold out of Halozyme (HALO) in Q2 2025, closing a stake of 23,096 shares — an estimated $1.47M sold.

B. Metzler seel. Sohn & Co first reported a position in HALO in Q1 2023 and held it in 9 quarters. The position peaked at $2.54M in Q2 2023. 551 funds tracked by Wall St. Rank hold HALO as of Q2 2025.

  • B. Metzler seel. Sohn & Co reported no remaining Halozyme position as of Q2 2025 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 23,096 Halozyme shares in Q2 2025, an estimated $1.47M.
  • B. Metzler seel. Sohn & Co first reported a position in Halozyme in Q1 2023 and held it in 9 quarters.
  • B. Metzler seel. Sohn & Co's Halozyme position peaked at $2.54M in Q2 2023.
  • 551 funds tracked by Wall St. Rank held Halozyme as of Q2 2025.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2025, filed 11 Aug 2025.